AURORA CANNABIS INC (ACB) Aurora Cannabis Inc. is a leading company in the global cannabis industry, focusing on the cultivation, production, and sale of various cannabis and cannabis-derived products across Canada and internationally. Beyond its core product offerings, the company engages in a broad spectrum of related activities, including the design and engineering of facilities, cannabis breeding programs, research and development, and both wholesale and retail distribution channels. For medical users, Aurora provides a diverse selection of products such as different strains of dried cannabis, cannabis oils, capsules, and topical kits. Their inventory also includes ancillary items like vaporizers, vaporizer accessories, herb mills (specifically for CanniMed products), grinders, and secure containers for vaporizers. The company is actively involved in developing advanced medical cannabis products, with ongoing work on oral, topical, edible, and inhalable formulations. Furthermore, Aurora manages CanvasRX, a network of centers dedicated to cannabis counseling and community outreach. Its service portfolio extends to providing patient support, specialized design and construction services, and comprehensive analytical testing for cannabis products. Aurora Cannabis Inc. manages an extensive collection of brands, including Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The company's main corporate office is located in Edmonton, Canada.
Sector: Medicinal Chemicals & Botanical Products
Industry: Drug Manufacturers - Specialty & Generic
Aurora Cannabis Inc. NASDAQ:ACB Healthcare · Drug Manufacturers - Specialty & Generic
CLOSED · Nov 6 $5.24 CLOSED · Nov 6 Prev close $5.19 Close $5.24 AH close $5.16 VOL 2.09M $ Vol $10.78M RVOL 1.30x
Mkt Cap $324.58M
VOL 2.09M sh
$ Vol $10.78M
RVOL 1.30×
Press Release ● Critical ⚠ 4
Aurora Cannabis Announces Fiscal 2027 Second Quarter Results
Aurora Cannabis reported fiscal Q2 2027 net revenue of $86.0 million, up 9% YoY, anchored by record international medical cannabis revenue of $61.4 million, up 44% on German and Polish patient demand.
The quarter was mixed beneath the headline: Canadian medical revenue fell 24% to $21.2 million on federal reimbursement changes, adjusted EBITDA slipped to $14.0 million from $15.4 million, and free cash flow remained an outflow at $17.5 million, though improved by $22.4 million year-over-year.
Aurora carries $133.0 million of cash and short-term investments with no debt. The company also cancelled its investor call following the November 3 announcement that Organigram will acquire all Aurora shares for C$7.80 in cash, 5.8626 Organigram shares, or a mixed consideration, expected to close in January 2027 pending approvals.
• 3d ago AI analysis › Press Release ● Major ⚠ 3
Curaleaf Issues Statement Regarding Alternative Proposal for Aurora Cannabis
Curaleaf publicly acknowledged Aurora's announcement of an alternative transaction with Organigram while stressing that Curaleaf's enhanced tender offer, first made August 18 and improved October 6, remains outstanding for all Aurora common shares.
Curaleaf argues its offer delivers better value, greater certainty and speed to close, and larger synergies, and faulted Aurora and Organigram for withholding material details such as any break fee, management composition, and investor rights granted to BAT.
The release sharply criticized Aurora's board for granting due diligence access to Organigram while refusing direct engagement with Curaleaf, which Curaleaf says blocks any chance of a further enhanced bid and constitutes a dereliction of fiduciary duties.
• 5d ago AI analysis › Press Release ● Critical ⚠ 3
Organigram to Acquire Aurora and Establish a Global Cannabis Leader
Organigram agreed to acquire Aurora Cannabis for C$7.80 per share, valuing Aurora at approximately C$561 million on a fully diluted basis.
The offer represents a 93% premium to Aurora's unaffected price and a 21% premium to Curaleaf's hostile bid, which Aurora's board unanimously rejected. Aurora shareholders can elect cash, 5.8626 Organigram shares, or a mix, subject to proration, and are expected to hold roughly 35% pro forma economic ownership of the combined company.
The deal has unanimous board support from both companies, C$50 million in identified synergies, and a fully committed financing package including a C$187.5 million BAT private placement and up to $210 million in ATB credit facilities. Closing is expected in January 2027, subject to shareholder, court, and regulatory approvals including German foreign investment clearance.
• 5d ago AI analysis › Press Release ⚠ 1
Aurora Cannabis to Host Second Quarter 2027 Investor Conference Call
Aurora Cannabis will host its fiscal Q2 2027 investor conference call on Thursday, November 12, 2026 at 8:00 a.m. ET, with financial results released before market open that morning.
CEO Miguel Martin and CFO Simona King will host the call and Q&A; a webcast is available via the company's investor site.
The release reiterates that shareholders are advised to reject Curaleaf's hostile bid by taking no action and not tendering their shares, directing investors to ProtectAurora.com.
• 10d ago AI analysis › Press Release ⚠ 2
Aurora Cannabis Announces the Alberta Securities Commission has dismissed Curaleaf's Application and ruled in favour of the Company's At-the-Market Program
The Alberta Securities Commission dismissed Curaleaf's application to halt Aurora Cannabis' at-the-market equity program, confirming the program's compliance with securities laws.
Aurora last used the ATM on August 18, 2026, and has not used it during the hostile bid process; the program was publicly disclosed in February 2026, months before Curaleaf's bid.
The board unanimously recommends shareholders reject Curaleaf's revised hostile bid by taking no action, and that shareholders who have tendered withdraw their shares, while a strategic alternatives process continues.
• 13d ago AI analysis › Press Release ● Major ⚠ 4
Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside
Aurora Cannabis' board, on the unanimous recommendation of its Special Committee, again advised shareholders to reject Curaleaf's revised hostile bid for all outstanding ACB shares.
The board says the revised offer significantly undervalues Aurora, which is debt-free with a strong cash position, and that the cash consideration would effectively be funded by Aurora shareholders' own balance-sheet cash.
Aurora's Special Committee is actively exploring strategic alternatives, having signed confidentiality and standstill agreements with multiple interested parties; Curaleaf's bid remains open until December 4, 2026.
Shareholders are advised to take no action, as tendering early could undermine the potential for a superior outcome from the strategic review.
• 25d ago AI analysis › Press Release ⚠ 2
Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower Output
Aurora Cannabis completed a major expansion of its EU-GMP facility in Leuna, Germany, renamed Aurora Horizon, more than doubling expected annual flower output at the site.
The expanded facility received an expanded EU-GMP license from Saxony-Anhalt authorities and now applies Aurora's Canadian cultivation practices and proprietary genetics from its Aurora Coast R&D site in British Columbia.
As one of only three domestic producers in Germany, Aurora positions the site to serve its fastest-growing market and strengthen European supply chain resilience; no specific financial figures for the investment were disclosed.
• 1mo ago AI analysis › Press Release ⚠ 2
Aurora Maintains Shareholder Recommendation to Take No Action at this Time as Curaleaf Has Yet to File Their Revised Hostile Bid
Aurora Cannabis reaffirmed its advice that shareholders take no action on Curaleaf's hostile takeover bid, noting Curaleaf has yet to formally file a revised offer.
Curaleaf announced its intention to revise the bid to US$5.00 per Aurora share — 0.4013 subordinate voting shares plus US$1.00 cash — and extended the offer expiry to December 4, 2026.
Aurora also claimed victory at the Alberta Securities Commission: Curaleaf agreed to add pro forma financials to its circular and extend the bid period, addressing deficiencies Aurora identified.
The Special Committee of independent directors will issue its formal recommendation via a Directors' Circular within 15 days of receiving the revised bid materials.
• 1mo ago AI analysis › Press Release ⚠ 3
Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure
Aurora Cannabis filed an application with the Alberta Securities Commission seeking an order requiring Curaleaf to correct deficiencies in its hostile bid circular and comply with securities laws.
The alleged deficiencies include missing pro forma financial statements, failure to observe the mandatory 105-day deposit period, and failure to publish French-language notice of the bid in Québec.
Aurora says Curaleaf's failure to meet the 105-day period means the bid does not qualify as a 'permitted bid' under Aurora's Shareholder Rights Plan, which would be triggered if Curaleaf acquires more than 20% of Aurora's shares.
Aurora's Board unanimously continues to recommend shareholders reject the bid by taking no action, not tendering, and withdrawing any already-tendered shares.
• 1mo ago AI analysis › Press Release ⚠ 4
Aurora Cannabis Provides Business Update; Accretive Acquisition of Safari Flower Company and Leading European Performance Expected to Fuel International Growth in the Fiscal Second Quarter 2027 and Beyond
Aurora Cannabis reaffirmed its fiscal 2027 second-quarter guidance for sequential growth in quarterly net revenue and adjusted EBITDA, a non-GAAP measure.
The recently EU-GMP-certified Safari Flower Company acquisition is expected to add incremental net revenue and adjusted EBITDA, while strength in Germany and Poland — including #1 market share by revenue in Poland — supports profitable international growth; UK expansion continues via the recently announced Internode Pharma and HAP Pharma Limited acquisitions.
The balance sheet holds $149 million in cash and no debt as of June 30, 2026, with the ATM program reserved for Board-approved use, though management says it will keep investing in the international business over the next several quarters.
• 1mo ago AI analysis › Press Release ⚠ 5
Aurora Cannabis Refutes Curaleaf's Latest Attempt To Distract Shareholders From The Facts
Aurora Cannabis publicly rebutted Curaleaf Holdings' application to halt Aurora's at-the-market equity program, calling the filing a distraction from a hostile bid that Aurora's board says significantly undervalues the company.
Aurora counterpunched at Curaleaf's own balance sheet, citing more than $1 billion of debt including $500 million carrying an 11.5% interest rate, while emphasizing that Aurora itself is debt-free with a strong cash position.
The board unanimously reiterated that shareholders should reject the hostile bid by taking no action and not tendering, and asked shareholders who already tendered to withdraw their shares. Aurora also noted it filed a complaint with the Alberta Securities Commission on September 2 over deficiencies in Curaleaf's bid.
• 1mo ago AI analysis › Press Release
Aurora Appoints Seasoned Biopharmaceutical Executive to Lead Commercial Acceleration of Global Medical Cannabis Business
Aurora Cannabis has appointed Faris El Refaie as Executive Vice President, Global Commercial, a newly created role effective September 28, 2026.
El Refaie brings 25 years of biopharmaceutical experience, with prior leadership roles at JAMP Pharma Group, GSK and AstraZeneca spanning commercial transformations across Canada, the U.S., Europe and Asia.
He will oversee Aurora's global commercial function and medical cannabis market strategy across Canada, Europe, Australia, New Zealand and other international markets as the company works to accelerate commercial capabilities and patient reach.
• 1mo ago AI analysis › Press Release ● Critical ⚠ 6
Curaleaf Responds to Aurora Circular; Reaffirms Offer as the Best Path to Value Creation for Shareholders
Curaleaf publicly rebutted Aurora Cannabis's Directors' Circular, reaffirming its hostile takeover offer and urging Aurora shareholders to tender, citing a 45% premium to the unaffected price and a US$5.00 cap representing an 82% premium to the 30-day VWAP as of August 10, 2026.
The release attacks Aurora's record: roughly US$398 million raised through dilutive issuances since September 2020 (~31% dilution), quarterly adjusted EBITDA down 63% since December 2025, negative operating cash flow of C$4.4 million in the June quarter, and KPMG's April 2024 resignation as auditor.
Curaleaf Chairman and CEO Boris Jordan said Aurora has never presented a counteroffer, escalating pressure on the board ahead of tender decisions; Aurora has not reviewed or confirmed the accuracy of the Aurora information cited in this bidder-authored release.
• 2mo ago AI analysis › Press Release ● Major ⚠ 4
Curaleaf Responds to Aurora Cannabis' Latest Attempt to Deflect From Shareholder Value Creation
Curaleaf Holdings escalated its hostile takeover efforts against Aurora Cannabis with a sharply worded rebuttal, criticizing Aurora's management for 'misleading statistics' and refusing constructive engagement.
Curaleaf detailed significant operational failures at Aurora, citing over C$400 million in impairments, a 35% share price decline over the past year, and negative operating cash flow of C$4.4 million in the June quarter.
Despite the aggressive tone, Curaleaf noted that Aurora's share price had risen since the initial bid was announced, arguing that the market recognizes the value of a combination while urging shareholders to demand results.
• 2mo ago AI analysis › Press Release ● Critical ⚠ 1
AURORA CANNABIS CORRECTS INACCURATE STATEMENTS MADE IN SUPPORT OF CURALEAF HOLDINGS' HOSTILE BID
Aurora Cannabis urged shareholders to take no action regarding Curaleaf Holdings' hostile takeover bid, asserting the offer attempts to undervalue its world-class EU-GMP infrastructure and global medical footprint.
The company defended its operational strength, citing 17% year-over-year growth in international net revenue and three consecutive years of positive adjusted EBITDA as evidence its transformation is working.
Management refuted Curaleaf's claims about its German business and highlighted recent acquisitions in the UK, emphasizing its position as a market leader in Poland and across Europe.
• 2mo ago AI analysis › Press Release
Aurora Cannabis Furthers Global Medical Cannabis Growth with Accretive Acquisition of Internode Pharma Limited and HAP Pharma Limited, Expanding Distribution Access to the UK Medical Cannabis Market
Aurora Cannabis acquired UK-based Internode Pharma Limited and HAP Pharma Limited for GBP 2.1 million in cash to establish a direct supply chain for the UK medical cannabis market.
The transaction adds a licensed import facility and a virtual pharmacy in Birmingham, serving a population of approximately 70 million people.
Management expects the move to be accretive to adjusted EBITDA by reducing third-party reliance and improving operational efficiencies.
• 2mo ago AI analysis › Press Release ● Critical ⚠ 1
AURORA CANNABIS INC. RESPONDS TO PRESS RELEASE OF CURALEAF HOLDINGS, INC. REGARDING INTENTION TO LAUNCH UNSOLICITED TAKE-OVER BID
Aurora Cannabis confirmed it received an unsolicited take-over bid from Curaleaf Holdings proposing US$4.00 per share, composed of US$0.75 cash plus 0.3463 of a Curaleaf subordinate voting share.
The Company noted the proposal includes a cap of US$5.00 per share, which it highlighted is lower than recent trading levels from December 2025, and emphasized its recent acquisition of Safari Flower Company as evidence of its standalone strategic plan.
A special committee of independent directors will be formed to review the Proposal, though Aurora affirmed it is not solicited and no decision has been made regarding the transaction.
• 2mo ago AI analysis › Press Release ● Critical ⚠ 2
Curaleaf Announces Intention to Launch Take-Over Bid for Aurora Cannabis to Solidify its Position as the Global Cannabis Industry Leader
Curaleaf Holdings announced its intention to launch a take-over bid for Aurora Cannabis, offering US$4.00 per share, representing a 45% premium to Aurora's 30-day VWAP.
The proposed consideration consists of 0.3463 Curaleaf shares plus US$0.75 in cash for each Aurora share, with a cap of US$5.00 per share to account for potential increases in Curaleaf's stock price.
Curaleaf stated the combined entity would generate over US$1.5 billion in LTM revenue and US$350 million in Adjusted EBITDA, targeting at least US$40 million in annual cost synergies and creating a leading global cannabis platform.
Aurora's board has refused to engage in discussions following private overtures beginning in June, prompting Curaleaf to take its proposal directly to shareholders.
• 2mo ago AI analysis › Press Release
Aurora, a Global Leader in Medical Cannabis, Announces Results of 2026 Annual General Meeting
Aurora Cannabis announced the voting results from its 2026 Annual General Meeting, confirming the re-election of all five director nominees with support ranging from 85.12% to 86.52%.
Shareholders also approved the appointment of Ernst & Young LLP as the company's auditor for the ensuing year and passed the advisory Say-on-Pay vote with 82.97% of votes cast in favor.
The meeting was represented by 16,639,306 common shares, approximately 26.86% of the company's issued and outstanding common shares as of the record date.
• 2mo ago AI analysis › Press Release ⚠ 3
Aurora Cannabis Announces Fiscal 2027 First Quarter Results
Aurora Cannabis reported fiscal Q1 2027 net revenue of $67.6 million, down 9% year-over-year, primarily due to a 25% decline in Canadian medical cannabis revenue following federal reimbursement cuts.
International medical revenue grew 17% to $43.3 million, driven by increased demand in Germany, while the company maintained a strong balance sheet with $149.1 million in cash and no debt.
The company also announced that its subsidiary Safari Flower Company received a three-year EU-GMP certification, bolstering its capacity in high-margin international markets.
• 3mo ago AI analysis › Press Release
Aurora Receives Support from Leading Independent Proxy Adviser Institutional Shareholder Services Inc. for the 2026 Annual General Meeting of Shareholders
Institutional Shareholder Services Inc. (ISS) has recommended that Aurora shareholders vote FOR all director nominees and meeting resolutions ahead of the 2026 Annual General Meeting.
CEO Miguel Martin welcomed the support, stating that ISS recognizes the company's strong governance framework, while the board unanimously recommends voting FOR the election of five directors, auditor appointment, and Say-on-Pay resolution.
The virtual AGM is scheduled for August 7, 2026, with a voting deadline of August 5, 2026; shareholders can access voting support via Kingsdale Advisors.
• 3mo ago AI analysis › Press Release
Safari Flower Company, a Wholly Owned Subsidiary of Aurora Cannabis, Receives EU-GMP Certification at Niagara Facility
Safari Flower Company, a wholly owned subsidiary of Aurora Cannabis, received European Union Good Manufacturing Practice certification for its Ontario facility.
The three-year certification strengthens Safari's ability to serve international medical cannabis markets in Germany, Poland, and the UK under strict quality regulations.
Aurora acquired the 59,000 square foot Niagara facility in April 2026 to expand its global manufacturing network and EU-GMP capacity.
• 3mo ago AI analysis › Press Release
Aurora Cannabis to Host First Quarter 2027 Investor Conference Call
Aurora Cannabis announced it will hold an investor conference call on August 5, 2026, to discuss its financial results for the first quarter of fiscal 2027.
The company intends to release its financial results prior to market open that same morning, with the call hosted by CEO Miguel Martin and CFO Simona King.
• 3mo ago AI analysis › Press Release
Aurora Named to TIME Canada's Best Companies 2026 List
Aurora Cannabis was named to TIME Canada's Best Companies 2026 list, marking the first time a cannabis company has received this recognition.
The award, presented in collaboration with Statista, evaluated companies based on employee satisfaction, revenue growth, and sustainability transparency.
CEO Miguel Martin attributed the milestone to the team's expertise and the company's continued progress in the global medical cannabis market.
• 4mo ago AI analysis › Press Release
Aurora Cannabis Inc. Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General Meeting of Shareholders
Aurora Cannabis announced that the management information circular for its upcoming annual general meeting of shareholders is now available and has been mailed to shareholders of record as of June 15, 2026.
The virtual meeting is scheduled for August 7, 2026, at 1:00 p.m. Eastern time, with a voting deadline of August 5, 2026.
The board recommends voting FOR all director nominees and meeting resolutions, and shareholders may contact Kingsdale Advisors for assistance with voting.
• 4mo ago AI analysis › Press Release ⚠ 5
Aurora Cannabis Announces Full Year and Fiscal 2026 Fourth Quarter Results with Record Annual Revenue and Adjusted EBITDA¹
Aurora Cannabis reported record fiscal 2026 annual revenue of $320.6 million and Adjusted EBITDA of $53.8 million, driven by 18% growth in global medical cannabis sales.
However, Q4 results showed significant weakness with Adjusted EBITDA falling 34% year-over-year to $9.2 million and free cash flow dropping 94% to $0.3 million, pressured by higher SG&A and margin compression.
The company completed the $26.5 million acquisition of Safari Flower Company to expand EU-GMP capacity, while exiting its low-margin consumer business and divesting its stake in Bevo Agtech.
Management guided for lower annual Adjusted EBITDA and declining total revenue in FY27, citing reduced government-reimbursed pricing in Canadian medical cannabis effective April 1, 2026.
• 4mo ago AI analysis › Press Release
Aurora Deepens its Impact for Veterans Across Canada
Aurora Cannabis announced expanded support for veteran communities across Canada through its Strains for Heroes program.
The company donates five percent of net profits from Strains for Heroes product sales to veteran-focused organizations, capped at C$200,000 annually.
Recent contributions support food security, mental health, and leadership development via partners such as the Veteran Association Food Bank and Sach in Motion.
• 5mo ago AI analysis › Press Release
Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2026 Investor Conference Call and File Related Year End Information
Aurora Cannabis has scheduled its fourth quarter and fiscal year 2026 investor conference call for Thursday, June 11, 2026, at 8:00 a.m. Eastern Time.
The company will report its financial results for the period before the opening of markets on that same day.
Executive Chairman and CEO Miguel Martin and CFO Simona King will host the call and subsequent question-and-answer period.
• 5mo ago AI analysis › Press Release
Aurora Granted Plant Breeders' Rights, Strengthening Leadership in Cannabis Science
Aurora Cannabis has been granted Plant Breeders' Rights in Canada for two proprietary cannabis cultivars, Farm Gas(™) and Driftwood Diesel(™).
These rights give Aurora exclusive control over the growth, propagation, and sale of these cultivars, which are core medical cannabis products available in Germany, Poland, UK, Canada, and Australia.
The certification reflects Aurora's advanced breeding program and its commitment to developing cultivars with consistent and reliable performance.
• 5mo ago AI analysis › Press Release
Aurora Advances Global Medical Cannabis Portfolio with New Product Launches Across Key International Markets
Aurora Cannabis is expanding its global medical portfolio with new dried flower, pre-roll, and pastille products launching in Canada, Germany, Poland, and Australia.
The rollout, scheduled through June, leverages the company's GMP-certified network to meet patient and prescriber demand in regulated international markets.
New offerings include high-potency cultivars in Europe, edible pastilles in Australia, and additional medical formats in Canada.
• 6mo ago AI analysis › Press Release
Aurora Recognized for Executive Gender Diversity by the Globe & Mail for Second Consecutive Year
prnewswire.com • 7mo ago 
